Articles
Advanced Driver Assistance Systems Market Size, Share, Growth and Trend Analysis Report
by Susan Hill Business ConsultantThe global rare hemophilia factors market size is anticipated to
reach USD 336.3 million by 2025, according to a new report by Grand View
Research, Inc., progressing at a CAGR of 5.1% during the forecast period.
Several factor concentrates gaining marketing approvals from regulatory bodies
such as the U.S. FDA are expected to provide a significant push to the market.
In addition, growing adoption of prophylaxis treatment by patients is expected
to boost the growth of the market in coming years. Patients with severe rare
hemophilia factor disorders are recommended prophylactic treatment to avoid
bleeding episodes and improve quality of life.
Favorable government initiatives and mandates to
increase diagnosis and treatment rates are escalating the growth of the market.
For instance, the U.S. Congress enacted the Orphan Drug Act (ODA) in 1983. From
1983 to 2015, around 3,647 drugs were designated the status of orphan drugs and
554 drugs were approved by the U.S. FDA. Several key market players in the
market are focusing on R&D to launch new products and solutions for the
treatment of rare hemophilia factor disorders. For instance, in October 2015,
FDA approved Coagadex for treatment of hereditary factor X deficiency.
Introduction of new factor concentrates is likely to bolster market growth over
the forecast period.
Further
key findings from the study suggest:
- Based on type, factor VII accounted for the largest share in 2016,
owing to higher prevalence of this deficiency
- Factor concentrates is anticipated to be the most promising segment,
registering a CAGR of 5.7% over the forecast period. This type of
treatment is considered to be the safest and most effective treatment for
rare hemophilia factor disorders
- Fresh frozen plasma is estimated to command just over 53.0% of the
market value by 2025
- Asia Pacific rare hemophilia factors market is expected to exhibit
the highest CAGR of over 5.5% during the same period. The growth of the
region can be attributed to wide base of population and high number of
consanguineous marriage
- Some of the key players in the market are Novo Nordisk; Biogen;
Bayer healthcare; Pfizer, Inc.; Baxalta; CSL Behring; and Bio Products
Laboratory Ltd.
Access
full research report on global rare hemophilia factors market:
www.grandviewresearch.com/industry-analysis/rare-hemophilia-factors-market
Sponsor Ads
About Susan Hill 
Business Consultant
145 connections, 2 recommendations, 567 honor points.Joined APSense since, September 25th, 2017, From California, United States.
Created on Feb 18th 2020 07:36. Viewed 320 times.
